Macrocyclic Ether Inhibitors for ROS1 and ALK Kinase Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ROS1-positive or ALK-positive cancers, particularly in the central nervous system (CNS), are associated with adverse reactions such as dizziness, ataxia, gait disturbance, paraesthesia, weight gain, and cognitive changes due to TRK inhibition, and there is a need for CNS-penetrant and TRK-sparing inhibitors effective against wild-type ROS1 kinase domain and resistance mutations.
Innovation Solution
Development of compounds of Formula (I) or their pharmaceutically acceptable salts, which are inhibitors of ROS1 and ALK, specifically designed to target cancer cells with mutations while sparing native TRKs, thereby minimizing adverse CNS reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRK inhibition is used to treat ROS1-positive or ALK-positive cancers, then cancer treatment efficacy is improved, but adverse CNS reactions occur
Solution Approach 1:
The patent extracts and eliminates the harmful TRK inhibition activity from the inhibitor molecule while preserving the desired ROS1 and ALK inhibition. This is achieved through selective molecular design that targets the ATP-binding pocket of ROS1 and ALK kinases with high specificity, preventing off-target binding to TRK receptors. The compound selectively binds to ROS1 and ALK based on subtle structural differences in their kinase domains, thereby treating cancer effectively without causing TRK-related adverse CNS reactions such as dizziness, ataxia, gait disturbance, paraesthesia, weight gain, and cognitive changes.
2Adaptability or versatility
If broad-spectrum kinase inhibition is used to target multiple resistance mutations, then activity against resistance mutations is improved, but TRK inhibition and adverse reactions increase
Solution Approach 1:
The patent applies local quality by designing the inhibitor with specific molecular features that match the local structural characteristics of ROS1 and ALK kinase domains, particularly in regions affected by resistance mutations. The compound's structure includes heteroaromatic rings and specific substituent patterns that form selective interactions with amino acid residues unique to ROS1 and ALK, allowing it to maintain high affinity for mutant forms while avoiding TRK binding. This localized molecular recognition enables broad-spectrum activity against resistance mutations without compromising selectivity.
3Reliability
If CNS-penetrant inhibitors are used to treat brain metastases, then CNS cancer treatment is improved, but TRK-related adverse reactions worsen
Solution Approach 1:
The patent employs the inhibitor compound as a selective intermediary that can cross the blood-brain barrier to treat CNS metastases while avoiding harmful interactions with TRK receptors in the CNS. The molecule's lipophilic properties and molecular weight allow it to penetrate the blood-brain barrier effectively, and its selective binding profile ensures that once in the CNS, it targets only ROS1 and ALK-positive tumor cells without inhibiting native TRKs, thereby treating brain metastases while sparing the healthy CNS from adverse reactions.
Data Source
AI summary
Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.